KATALYST DIAGNOSTICS acquired by CRUINN DIAGNOSTICS
Context
Announced on September 24, 2026, Cruinn Diagnostics’ acquisition of Katalyst Diagnostics brings together two complementary distribution specialists to build an integrated healthcare platform generating €50M in annual sales. The cross-border deal represents the first step in Cruinn’s buy-and-build strategy in the UK, aimed at scaling combined revenue toward €150 million. Backed by a team of over 100 employees across regional hubs, Katalyst will retain its current leadership team, with CEO Afsheen Khan continuing to direct UK operations. Cruinn CEO Peter Hussey framed the move as an entry point into Britain, connecting Katalyst’s established NHS relationships, sales network, and point-of-care portfolio with Cruinn’s core laboratory diagnostic and calibration services. Looking ahead, Cruinn plans to leverage this expanded footprint to pursue targeted add-on acquisitions across continental Europe.
KATALYST DIAGNOSTICS, which reported an EBITDA margin of in 2026, is valued in this transaction at an EV/EBITDA multiple of , a level to compare with the average currently observed in the Business Services sector (11.4x).
-> Deep-dive in Business Services market trends
Target
Headquartered in the UK, Katalyst Diagnostics supplies point-of-care testing technologies, specialized diagnostic instrumentation, and clinical support across the British healthcare sector. The company partners directly with NHS hospital trusts as well as private and specialized medical facilities nationwide. Its portfolio centers on decentralized diagnostic devices built for fast, targeted use across key specialties, including psychiatry, oncology, pediatrics, and emergency care. Led by CEO Afsheen Khan, Katalyst combines product distribution with dedicated account management and hands-on clinical support tailored to the daily demands of healthcare providers.
Ent. Value
Equity Value
Multiples
EV / Revenue
EV / EBITDA
EV / EBIT
Historical Financials (EUR)
Similar deals in B2B Specialized Distribution
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 10/2026 | WATERLAND | TERR ASIA | FRANCE | B2B Specialized Distribution |
| 09/2026 | Agri Exotic Trading | Mellone Wholesale Produce | UNITED STATES | B2B Specialized Distribution |
| 09/2026 | C&C GROUP | NECTAR IMPORTS | UNITED KINGDOM | B2B Specialized Distribution |
| 07/2026 | H2 Equity Partners | Lynch Medical Supplies | IRELAND | Hospitality Supplies |
| 06/2026 | CREDIT MUTUEL EQUITY | ONELEC | FRANCE | B2B Specialized Distribution |
| 04/2026 | FASSI GROUP | FASCAN INTERNATIONAL | UNITED STATES | B2B Specialized Distribution |
| 03/2026 | ONE EQUITY PARTNERS | KITWAVE GROUP | UNITED KINGDOM | B2B Specialized Distribution |
| 03/2026 | ITAL EXPRESS | DIEDERICHS KAROSSERIETEILE | GERMANY | B2B Specialized Distribution |
| 03/2026 | BAIN CAPITAL | Tingstad | SWEDEN | Hospitality Supplies |
| 01/2026 | GROUPE BRUNEAU | OFFICEEASY | FRANCE | Office Supplies & Furniture |
REFERENCES
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of KATALYST DIAGNOSTICS by CRUINN DIAGNOSTICS are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
Target: katalyst diagnostics
Acquirer: cruinn diagnostics